Tell EPA: Bring Back my Primatene
When the EPA banned
Primatene Mist for sale at the end of 2011, it took
away the only over-the-counter inhaler to help
asthmatics and COPD sufferers cope with their
symptoms including shortness of breath.
Without Primatene Mist, Americans lacking health
insurance or the means to afford a doctor's visit
and costly prescription inhalers either need to go
to the emergency room -- which can cost thousands of
dollars -- or simply endure the pain and shortness
of breath. Neither is acceptable.
The EPA claims it banned the inhaler because it
contains chlorofluorocarbons (CFCs), which could
contribute to global warming. However, the EPA
allows the sale of some prescription inhalers which
contain CFCs. The EPA also has no idea how to
dispose of the existing Primatene Mist inhalers
without letting those CFCs escape into the
environment. For both of these reasons, the EPA's
decision to block the sale of the approximately one
million Primatene Mists collecting dust on warehouse
shelves goes against common sense.
Notably, Armstrong Pharmaceuticals a subsidiary of
Amphastar Pharmaceuticals and the maker Primatene
Mist has promised to donate all the net profits from
the sale of Primatene Mist to charity, which could
total in the millions.
The EPA should do the right thing and put Primatene
Mist back on the market immediately. Protecting the
environment is important -- but it should not come
at the cost of the health of millions of asthma and
Please join this campaign: